Abstract
Investigations covered the possible hematotoxic effect of eugenol in rats following two-week and four-week continuous p.o. application. An experiment was conducted on 72 maleWistar rats divided into six groups. Four groups were treated with different doses of eugenol (10 mg/kg bm/day, 50 mg/kg/day, 200 mg/kg/day and 400 mg/kg bm/day), the control group was administered a vehiculum (0,5 % methylcellulose, 20 % propylene glycol and water), and the sixth group was the absolute untreated control. Eugenol and the vehiculum were administered using a gastric probe in a volume of 1 ml/100 g body mass of rat. Blood was sampled using cardiac puncture on days 14 and 28 of the experiment in order to determine hematological parameters (hematocrit, number of erythrocytes, MCV, haemoglobin concentration, MCH, number of leukocytes, leukocyte formula, and number of thrombocytes). The results have shown that eugenol administered over 14 and 28 days in doses of 10, 50, 200 i 400 mg/kg bm/day has no hemolytic activity. Furthermore, administered over four weeks, it does not significantly affect the number of erythrocytes, haemoglobin concentration, hematocrit, erythrocyte volume, number of leukocytes, and the leukocyte formula. Applied over two weeks, eugenol causes a significant increase in the mass of haemoglobin per erythrocyte, in comparison with controls. This effect is non-specific and does not depend on the dose or on the duration of treatment. The eugenol doses of 10 and 200 mg/kg/day administered over a period of four weeks result in a statistically significant reduction in the number of thrombocytes in comparison with the absolute control, while the highest investigated dose (400 mg/kg) causes a significant increase in comparison with the numbers for rats treated with a dose of 10 and 200 mg/kg/day. The changes in thrombocyte number caused by eugenol are qualitatively different and depend neither on the dose nor on the duration of treatment. Eugenol applied over two or four weeks does not exhibit a significant influence on the number of lymphocytes, monocytes or granulocytes.
Highlights
Rezultati su pokazali da eugenol primenjivan 14 i 28 dana u dozama od [10, 50, 200] i 400 mg/kg tm/dan nema hemoliti~ku aktivnost
Posle dvonedeljne primene eugenol prouzrokuje zna~ajno pove}anje prose~ne mase hemoglobina po eritrocitu (MCH) kod pacova tretiranih dozom od 200 mg/kg/dan u odnosu na kontrolne i u odnosu naivotinje tretirane dozom od 50 mg/kg/dan (p
3. Eugenol primenjivan tokom dve i ~etiri nedelje nije zna~ajno uticao na prose~an broj limfocita, monocita i granulocita u pore|enju sa kontrolnim grupama pacova
Summary
Rezultati su pokazali da eugenol primenjivan 14 i 28 dana u dozama od [10, 50, 200] i 400 mg/kg tm/dan nema hemoliti~ku aktivnost. Prose~an broj eritrocita kod kontrolnih grupa pacova (AK, K) i grupa tretiranih eugenolom (10, 50, 200 i 400 mg/kg/dan) ustanovljen dve i ~etiri nedelje posle po~etka eksperimenta nije se statisti~ki zna~ajno razlikovao (tabele 1 i 2).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
